5/23/2013

Apexigen, which specializes in developing new cancer drugs using rabbit-derived, humanized monoclonal antibodies, secured $15 million in an equity round. APX005, the California-based firm's lead drug candidate, is under development as a treatment for pancreatic cancer and other difficult-to-treat cancers.

Full Story:
MedCityNews.com

Related Summaries